Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Theodore

Showing results (221-230 of 237) with videos related to

Pageof 24
Sort By:
Neurology and Therapy|December 15, 2015
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing ExperienceRalf Gold, J Theodore Phillips, Eva Havrdova, et al.
Annals of Clinical and Translational Neurology|March 10, 2015
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsVissia Viglietta, David Miller, Amit Bar-Or, et al.
Bioconjugate Chemistry|November 8, 2011
Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177LuHuma Mohsin, Fang Jia, Jeffrey N Bryan, et al.
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotinZhengsheng Yao, Meili Zhang, Kayhan Garmestani, et al.
Archives of Neurology|October 13, 2006
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosisOlaf Stüve, Christina M Marra, Amit Bar-Or, et al.
Clinical Therapeutics|June 11, 2004
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips, George Rice, Elliot Frohman, et al.
Cancer Research|October 18, 2002
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotinZhengsheng Yao, Meili Zhang, Donald B Axworthy, et al.
Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.
Neurology|March 29, 2019
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practiceDevangi Mehta, Catherine Miller, Douglas L Arnold, et al.
Pageof 24

Showing results (221-230 of 237) with videos related to

Sort By:
Pageof 24
Neurology and Therapy|December 15, 2015
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing ExperienceRalf Gold, J Theodore Phillips, Eva Havrdova, et al.
Annals of Clinical and Translational Neurology|March 10, 2015
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trialsVissia Viglietta, David Miller, Amit Bar-Or, et al.
Bioconjugate Chemistry|November 8, 2011
Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177LuHuma Mohsin, Fang Jia, Jeffrey N Bryan, et al.
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotinZhengsheng Yao, Meili Zhang, Kayhan Garmestani, et al.
Archives of Neurology|October 13, 2006
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosisOlaf Stüve, Christina M Marra, Amit Bar-Or, et al.
Clinical Therapeutics|June 11, 2004
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips, George Rice, Elliot Frohman, et al.
Cancer Research|October 18, 2002
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotinZhengsheng Yao, Meili Zhang, Donald B Axworthy, et al.
Neurology|February 15, 2015
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H Miller, Robert J Fox, J Theodore Phillips, et al.
Neurology|March 29, 2019
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practiceDevangi Mehta, Catherine Miller, Douglas L Arnold, et al.
Pageof 24